VTRS Q3 2025 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.8B+0.2% YoY

Gross Profit

$1.4B36.8% margin

Operating Income

$252M6.7% margin

Net Income

-$128M-3.4% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$745M

Free Cash Flow

$645M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$37.9B

Total Liabilities

$22.7B

Stockholders' Equity

$15.2B

Cash & Equivalents

$975M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.8B	+0.2%
Gross Profit	$1.4B	$1.5B	-5.1%
Operating Income	$252M	$226M	+11.4%
Net Income	-$128M	$95M	-235.2%

Revenue Segments

Brands

$2.4B65%

Generics

$1.3B35%

Geographic Segments

Developed Markets Segment

$2.3B60%

Greater China Segment

$615M16%

Emerging Markets Segment

$572M15%

Japan, Australia and New Zealand Segment

$307M8%